Pharmacokinetics and effects of formoterol fumarate in healthy human subjects after oral dosing

European Journal of Clinical Pharmacology

Volumn 54, Issue 6, 1998, Pages 463-468

  Van Den Berg, B T J ^a   Braat, M C P ^a   Van Boxtel, C J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Eosinophils; Formoterol

Indexed keywords

FORMOTEROL FUMARATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; EOSINOPHIL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADRENERGIC BETA-AGONISTS; ADULT; BRONCHODILATOR AGENTS; EOSINOPHILS; ETHANOLAMINES; HUMANS; MALE; POTASSIUM; REFERENCE VALUES; TIME FACTORS;

EID: 0031686107     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050494     Document Type: Article

References (34)

1. Barnes PJ (1993) Beta-adrenoceptors on smooth muscle, nerves and inflammatory cells. Life Sci 52: 2101-2109
2. Ramsdale EH, Otis J, Kline PA, Gontovnick LS, Hargreave FE, O'Byrne PM (1991) Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formolerol. Am Rev Respir Dis 143: 998-1001
3. Stam J, Souren M, Zweers PG (1993) The onset of action of formoterol, a new beta 2 adrenoceptor agonist. Int J Clin Pharmacol Ther Toxicol 31: 23-26
4. Derom EY, Pauwels RA (1992) Time course of bronchodilating effect of inhaled formoterol, a potent and long-acting sympathomimetic. Thorax 47: 30-33
5. Chetta A, Del Donno M, Maiocchi G, Pisi G, Moretti D, Olivieri D (1993) Prolonged bronchodilating effect of formoterol versus procaterol in bronchial asthma. Ann Allergy Asthma Immunol 70: 171-174
6. Malo JL, Cartier A, Trudeau C, Ghezzo H, Gontovnick L (1990) Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. Am Rev Respir Dis 142: 1147-1152
7. McAlpine LG, Thomson NC (1990) Prophylaxis of exercise-induced asthma with inhaled formoterol, a long-acting beta 2-adrenergic agonist. Respir Med 84: 293-295
8. Nix A, Nichol GM, Robson A, Barnes PJ, Chung KF (1990) Effect of formoterol, a long-lasting beta 2-adrenoceptor agonist, against methacholine-induced bronchoconstriction. Br J Clin Pharmacol 29: 321-324
9. Crane J, Pearce N, Flatt A (1989) Prescribed fenoterol and death from asthma in New Zealand 1981-83: a case control study. Lancet 11: 917-922
10. Pearce N, Grainger J, Atkinson M, Crane J, Burgess C, Culling C, Windom H, Beasley R (1990) Case control study of prescribed fenoterol and death from asthma in New Zealand 1977-81. Thorax 45: 170-175
11. Clausen T, Flatman JA (1980) Beta 2-adrenoceptors mediate the stimulatory effect of epinephrine on active electrogenic Na-K transport in rat soleus muscle. Br J Pharmacol 68: 749-755
12. Braat MCP, Jonkers RE, van Boxtel CJ (1992) Quantification of metoprolol beta 2-adrenoceptor antagonism in asthmatic patients by pharmacokinetic-pharmacodynamic modelling. Pulm Pharmacol 5: 31-38
13. Reed CE (1994) The importance of eosinophils in the immunology of asthma and allergic disease. Ann Allergy Asthma Immunol 72: 376-380
14. Janson C, Herala M (1992) Blood eosinophil count as risk factor for relapse in acute asthma. Respir Med 86: 101-104
15. Holgate ST, Roche WR, Church MK (1991) The role of the eosinophil in asthma. Am Rev Respir Dis 143: S66-70
16. Van den Berg BTJ, Portier EJG, van den Berg M, Braat MCP, van Boxtel CJ (1994) First high-performance liquid chromatography assay of formoterol concentrations in the low pg ml range. Ther Drug Monit 16: 196-199
17. Metzler CM, Elfring DL, McEvan AJ (1974) The user's manual for NONLIN and associated programs. Upjohn, Kalamazoo, Mich
18. Gibaldi M, Perrier D (1975) Pharmacokinetics. Dekker, New York
19. Holford NHG, Sheiner LB (1982) Kinetics of pharmacological response. Pharmacol Ther 16: 143-166
20. Oosterhuis B, Braat MCP, Roos CM, Wemer J, van Boxtel CJ (1986) Pharmacokinetic-pharmacodynamic modeling of terbutaline bronchodilation in man. Clin Pharmacol Ther 40: 469-475
21. Koopmans RP, Jonkers RE, Braat MCP, van Boxtel CJ (1995) Pharmacokinetic-pharmacodynamic modelling as applied to bronchial asthma. Clin Pharmacokinet 29: 213-220
22. Lofdahl CG, Svedmyr N (1989) Formoterol fumarate, a new beta 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration. Allergy 44: 264-271
23. Morgan DJ (1990) Clinical pharmacokinetics of beta-agonists. Clin Pharmacokinet 18: 270-294
24. Walker SR, Evans ME, Richards AJ, Paterson JW (1972) The clinical pharmacology of oral and inhaled salbutamol. Clin Pharmacol Ther 13: 861-867
25. Hörnblad Y, Ripe E, Magnusson PO, Tegnér K (1976) The metabolism and clinical activity of terbutaline and its prodrug ibuterol. Eur J Clin Pharmacol 10: 9-18
26. Van den Berg W, Leferink JG, Tabingh Suermondt W, Kreukniet J, Maes RAA, Serra R, Bruynzeel PLB (1983) Terbutaline serum concentrations related to different lung function parameters and beta-receptor function. Int J Clin Pharmacol Ther Toxicol 21: 24-30
27. Fairfax AJ, McNabb WR, Davies HJ, Spiro SG (1980) Slow-release oral salbutamol and aminophylline in nocturnal asthma: relation of overnight changes in lung function and plasma drug levels. Thorax 35: 526-530
28. Morgan DJ, Paull JD, Richmond BH, Wilson-Evered E, Ziccone SP (1986) Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol 22: 587-593
29. Van Boxtel CJ, Holford NHG, Danhof M (1992) The in vivo study of drug action. Elsevier, Amsterdam
30. Fuglsang G, Pedersen S, Borgström L (1989) Dose-response relationship of intravenously administrated terbutaline in children with asthma. J Pediatr 114: 315-320
31. Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE (1990) Bronchodilator, cardiovascular and hypokalaemic effects of fenoterol, salbutamol and terbutaline in asthma. Lancet 336: 1396-1399
32. Hochhaus G, Möllmann H (1992) Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol 30: 342-362
33. Jonkers RE, van Boxtel CJ, Oosterhuis B (1987) Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol. Clin Pharmacol Ther 42: 627-633
34. Butter JJ, van den Berg BTJ, Portier EJG, Kaiser G, van Boxtel CJ (1996) Determination by HPLC with electrochemical detection of formoterol RR and SS enantiomers in urine. J Liquid Chromatogr Rel Tech 19: 993-1005